This could be a key move for future growth.

Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may ...

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite ...

June 26 (Reuters) - Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it ...

Rituximab and ocrelizumab go head to head in randomized trial ...

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with ...

Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis, revealing plans to part ways with some of the biotech’s staffers and halt work on most of its research programs ...

In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more.

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum ...

CHARLOTTE, N.C. — Switching from high-efficacy therapies to a fumarate was associated with sustained disease control and a lower rate of infection in patients with multiple sclerosis (MS), results ...

TG Therapeutics, Inc. boosts anti-CD20 share as Q1 revenue jumps 69.6% to $204.9M, but overbought signals hint at a near-term ...